Feb 14, 2024 Life sciences – what to expect in 2024 By Harriet Hanks Emma Franck-Gwinnell Adam Golden 2023 was marked by some real success stories in the life sciences and healthcare space, including ground-breaking new weight loss...
Dec 14, 2023 What is the Actual Impact of the Biden Administration’s New March-In Guidance? By Kristen Riemenschneider Joshua Samuel The Bayh-Dole Act of 1980 provides certain rights in favor of the U.S. government in order to ensure that products arising from federally...
Jun 07, 2023 Return of the CVR By Adam Golden Mark Appleton The recent surge in bolt-on M&A in the life sciences sector is being fueled by the use of contingent value rights. Notwithstanding...
May 30, 2023 Key Takeaways from the 21st Annual Biomed Israel Conference By Ben Cohen The 21st annual Biomed Israel Conference, attended by thousands of industry leaders from 45 countries, presented a juxtaposition of...
May 24, 2023 Ongoing Initiatives at the USPTO and FDA and Their Potential Impact on the Life Sciences Industry in the United States By Kristen Riemenschneider Jeff Jay Jake Silvers In the past few months, proposals from the United States Patent and Trademark Office (“USPTO”) have drawn the attention of organizations,...
May 23, 2023 2023 ACC Life Sciences Conference: Structuring Considerations for Biotechs By Jeff Jay Jake Silvers The Association of Corporate Counsel hosted its annual Life Sciences Conference from May 9-11, 2023, which featured presentations from a...
Apr 12, 2023 The Drug Pricing Landscape in 2023: The Shifting Sands of Progress By Kristen Riemenschneider Joshua Samuel In our January blog post on this topic, The Drug Pricing Landscape in 2023: Renewed Pressure for Pricing Reform, we speculated that in...
Mar 06, 2023 Bridging Valuation Gaps in Public M&A in the Pharma, Biotech, and Other Life Sciences Industries By Jenny Hochenberg Adam Golden Acquisitions of public companies in pharma, biotech, and other life sciences industries are increasingly using deal structures designed...
Sep 15, 2022 Illumina/Grail: A Tale of Transatlantic Entropy By Thomas Lübbig Justin Stewart-Teitelbaum Laura Onken Lauren Vaca Amaryllis Müller Karen Slaney +3 more... Show less This isn’t the first time we’ve written about this US-focused transaction in the innovative markets for next generation gene sequencing...
Jul 01, 2022 Milestone Payments In Life Sciences M&A And Licensing Transactions By Adam Golden Jeff Jay This article originally appeared in Life Science Leader on July 1, 2022. As has now become an annual tradition, when the calendar turned...
Jun 21, 2022 Life Sciences Under the US Antitrust Microscope By Justin Stewart-Teitelbaum Laura Onken Lauren Vaca Under the Biden Administration, the US Federal Trade Commission (FTC) has prioritized aggressive antitrust enforcement, including in the...
Mar 25, 2022 US NIST Publishes AI Risk Management Framework and Updates on Tackling Bias in AI By Vinita Kailasanath Sora Park The National Institute of Standards and Technology (NIST) has announced its publication of an initial draft of the AI Risk Management...